USMLE – What's It
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
General Pathomorpholog.Pdf
Ukrаiniаn Medicаl Stomаtologicаl Аcаdemy THE DEPАRTАMENT OF PАTHOLOGICАL АNАTOMY WITH SECTIONSL COURSE MАNUАL for the foreign students GENERАL PАTHOMORPHOLOGY Poltаvа-2020 УДК:616-091(075.8) ББК:52.5я73 COMPILERS: PROFESSOR I. STАRCHENKO ASSOCIATIVE PROFESSOR O. PRYLUTSKYI АSSISTАNT A. ZADVORNOVA ASSISTANT D. NIKOLENKO Рекомендовано Вченою радою Української медичної стоматологічної академії як навчальний посібник для іноземних студентів – здобувачів вищої освіти ступеня магістра, які навчаються за спеціальністю 221 «Стоматологія» у закладах вищої освіти МОЗ України (протокол №8 від 11.03.2020р) Reviewers Romanuk A. - MD, Professor, Head of the Department of Pathological Anatomy, Sumy State University. Sitnikova V. - MD, Professor of Department of Normal and Pathological Clinical Anatomy Odessa National Medical University. Yeroshenko G. - MD, Professor, Department of Histology, Cytology and Embryology Ukrainian Medical Dental Academy. A teaching manual in English, developed at the Department of Pathological Anatomy with a section course UMSA by Professor Starchenko II, Associative Professor Prylutsky OK, Assistant Zadvornova AP, Assistant Nikolenko DE. The manual presents the content and basic questions of the topic, practical skills in sufficient volume for each class to be mastered by students, algorithms for describing macro- and micropreparations, situational tasks. The formulation of tests, their number and variable level of difficulty, sufficient volume for each topic allows to recommend them as preparation for students to take the licensed integrated exam "STEP-1". 2 Contents p. 1 Introduction to pathomorphology. Subject matter and tasks of 5 pathomorphology. Main stages of development of pathomorphology. Methods of pathanatomical diagnostics. Methods of pathomorphological research. 2 Morphological changes of cells as response to stressor and toxic damage 8 (parenchimatouse / intracellular dystrophies). -
Clinical an Urgent Care Approach to Complications and Conditions of Pregnancy Part 2
Clinical An Urgent Care Approach to Complications and Conditions of Pregnancy Part 2 Urgent message: From pregnancy confirmation to the evaluation of bleeding, urgent care centers are often the initial location for management of obstetric-related issues. Careful use of evidence-based guidelines is the key to successful outcomes. DAVID N. JACKSON, MD, FACOG and PETAR PLANINIC, MD, FACOG Introduction rgent care providers are called upon to manage a Uvariety of complaints in pregnancy. Some conditions can be managed at the urgent care center whereas others require stabilization and transport to a center with expert obstetrical capabilities. In all situations, practitioners should consider that a gestational age of fetal viability (many centers now use 23 to 24 weeks) is best served with referral for continuous fetal monitor- ing if there is bleeding, trauma, significant hypertension, relative hypoxemia (O2 saturation less than 95% for pregnant women), or contractions. Part 2 of this two- part series will discuss: Ⅲ Bleeding in pregnancy Ⅲ Ectopic gestation Ⅲ Trauma and pregnancy Ⅲ Acute abdominal pain in pregnancy Dr. Jackson is Professor of Maternal-Fetal Medicine at the University of Nevada, School of Medicine, Las Vegas, Nevada. Dr. Planinic is Assistant Professor of Obstetrics and Gynecology at the University of Nevada, School of Medicine, Las Vegas, Nevada. © gettyimages.com www.jucm.com JUCM The Journal of Urgent Care Medicine | September 2013 9 AN URGENT CARE APPROACH TO COMPLICATIONS AND CONDITIONS OF PREGNANCY Figure 1. Bleeding endocervical polyp with Evaluation of vaginal bleeding should follow a sys- inflammation tematic process. History of last menses and sexual activ- ity determines the possibility of pregnancy. -
HHS Public Access Author Manuscript
HHS Public Access Author manuscript Author Manuscript Author ManuscriptObstet Gynecol Author Manuscript. Author Author Manuscript manuscript; available in PMC 2016 January 12. Published in final edited form as: Obstet Gynecol. 2013 October ; 122(4): 885–900. doi:10.1097/AOG.0b013e3182a5fdfd. Prophylaxis and Treatment of Anthrax in Pregnant Women: A Systematic Review of Antibiotics Dana Meaney-Delman, MD MPH1, Sonja A. Rasmussen, MD MS1, Richard H. Beigi, MD2, Marianne E. Zotti, DrPH1, Yalonda Hutchings, MD MPH1, William A. Bower, MD1, Tracee A. Treadwell, DVM MPH1, and Denise J. Jamieson, MD MPH1 1Centers for Disease Control and Prevention, Atlanta, Georgia 2Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Reproductive Infectious Diseases and Obstetric Specialties, Magee-Women’s Hospital of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Abstract Objective—To review the safety and pharmacokinetics of antibiotics recommended for anthrax post-exposure prophylaxis and treatment in pregnant women. Data Sources—Articles were identified in the PUBMED database from inception through December 2012 by searching the keywords ([“pregnancy]” and [generic antibiotic name]). Additionally, hand searches of references from REPROTOX, TERIS, review articles and Briggs’ Drugs in Pregnancy and Lactation were performed. Methods of Study Selection—Articles included in the review contain primary data related to the safety and pharmacokinetics among pregnant women of five antibiotics recommended for anthrax post-exposure prophylaxis and treatment (ciprofloxacin, levofloxacin, moxifloxacin, doxycycline, amoxicillin), and of nine additional antibiotics recommended as part of the treatment regimen (penicillin, ampicillin, linezolid, clindamycin, meropenem, doripenem, rifampin, chloramphenicol, or vancomycin). Tabulation, Integration and Results—The PUBMED search identified 3850 articles for review. -
WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA). -
Cytomegalovirus Infection of the Human Gastrointestinal Tract
Journal of Gastroenterology and Hepatology (1999) 14, 973–976 OESOPHAGOGASTRODUODENAL DISORDERS Cytomegalovirus infection of the human gastrointestinal tract SUSAMA PATRA, SUBASH C SAMAL, ASHOK CHACKO, VADAKENADAYIL I MATHAN1 AND MINNIE M MATHAN1 The Wellcome Trust Research Laboratory, Department of Gastrointestinal Sciences, Christian Medical College and Hospital,Vellore,India Abstract Background: Current interest in cytomegalovirus (CMV) is largely due to an increase in the number of cases of acquired immunodeficiency syndrome and organ transplantation in recent years.The proper recognition of CMV-infected cells in gastrointestinal mucosal biopsies is critical for effective treatment of this condition. Methods: A total of 6580 endoscopic mucosal biopsies from 6323 patients in the 8-year period (1989–1996) were examined for CMV inclusion bodies. The endoscopic appearance and particularly the presence of ulcers were also analysed. Results and Conclusions: The prevalence of cytomegalovirus (CMV) inclusions was 9 per thousand in the gastrointestinal mucosal biopsies from an unselected group of patients. Of the 54 patients with CMV infection, 37 were immunocompromised and 17 apparently immunocompetent. Typical Cowdry inclusions and atypical inclusions were present, the latter more frequently in immunocompromised patients. The maximum prevalence of inclusions was in the oesophageal mucosa in immunocompro- mised individuals. © 1999 Blackwell Science Asia Pty Ltd Key words: cytomegalovirus, gastrointestinal tract, immunocompetent, immunocompromised, inclu- sion bodies, mucosal biopsies. INTRODUCTION in haematoxylin and eosin (HE)-stained histological samples is regarded as being sensitive and specific for Cytomegalovirus (CMV), first described in 1956,1 is a CMV infection,6–9 especially for samples from the gas- double-stranded DNA virus belonging to the herpes trointestinal tract. -
Haemosiderin-Laden Macrophages in the Bronchoalveolar Lavage Fluid of Patients with Diffuse Alveolar Damage
Eur Respir J 2009; 33: 1361–1366 DOI: 10.1183/09031936.00119108 CopyrightßERS Journals Ltd 2009 Haemosiderin-laden macrophages in the bronchoalveolar lavage fluid of patients with diffuse alveolar damage F. Maldonado*, J.G. Parambil*, E.S. Yi#, P.A. Decker" and J.H. Ryu* ABSTRACT: Quantification of haemosiderin-laden macrophages in bronchoalveolar lavage fluid AFFILIATIONS (BALF) has been used to diagnose diffuse alveolar haemorrhage (DAH) but has not been *Divisions of Pulmonary and Critical Care Medicine and, assessed in patients with diffuse alveolar damage (DAD). "Biostatistics. The present study analysed BALF obtained from 21 patients with DAD diagnosed by surgical #Dept of Laboratory Medicine and lung biopsy. Pathology The median age of 21 patients with DAD was 68 yrs (range 18–79 yrs); 14 (67%) were male and Mayo Clinic, Rochester, MN, USA. 12 (57%) were immunocompromised. The median proportion of haemosiderin-laden macro- CORRESPONDENCE phages in BALF was 5% (range 0–90%), but was o20% in seven (33%) patients, fulfilling the J.H. Ryu commonly used BALF criterion for DAH. There was a trend toward a positive correlation between Division of Pulmonary and Critical the percentage of haemosiderin-laden macrophages in BALF and parenchymal haemorrhage Care Medicine, Gonda 18 South Mayo Clinic assessed semiquantitatively by histopathological analysis. Patients with o20% haemosiderin- 200 1st St SW laden macrophages in BALF showed a significantly increased mortality rate (p50.047) compared Rochester to those with ,20%. MN 55905 In patients with an acute onset of diffuse lung infiltrates and respiratory distress, o20% USA Fax: 1 5072664372 haemosiderin-laden macrophages in BALF can occur with DAD, and is not necessarily diagnostic E-mail: [email protected] of DAH. -
Immunology of Tuberculosis
Color code: Important in red Extra in blue Immunology of Tuberculosis Editing file Objectives ➢ To know how M. tuberculosis infection is contracted and its initial encounter with the immune system ➢ To understand the delayed type of hypersensitivity reaction against M. tuberculosis ➢ To be familiar with the possible outcomes of the infection with M. tuberculosis in immunocompetent and immunocompromised hosts ➢ To understand the basis of the tuberculin test and its importance in gauging immunity against M. tuberculosis Introduction to Tuberculosis ➢ Mycobacterium tuberculosis is the second most common infectious cause of death in adults worldwide, with an increasing incidence due to HIV. ➢ TB is transmitted through aerosols (airborne transmission) by coughing or sneezing and acquired mainly through inhalation. ➢ The clinical development of the disease depends solely on the effectiveness of the host’s innate and adaptive immune response to the infection. If the immune response is functioning well, the clinical disease has little to no chance of developing. Tuberculosis is able to withstand the body’s immune response after being phagocytosed by several ways, including: Virulence factors Host factors The lipid-rich Waxy outer coat blocks Resistance to reactive oxygen intermediates. phagocytic enzymes. Catalase-peroxidase resists the host cell Inhibition of phagosome-lysosome fusion oxidative response. The glycolipid Lipoarabinomannan (LAM) Inhibition of phagosome acidification. Stimulates cytokines, resists the host oxidative (prevents digestion -
Effect of Synbiotic on the Treatment of Jaundice in Full Term Neonates: a Randomized Clinical Trial
Pediatr Gastroenterol Hepatol Nutr. 2019 Sep;22(5):453-459 https://doi.org/10.5223/pghn.2019.22.5.453 pISSN 2234-8646·eISSN 2234-8840 Original Article Effect of Synbiotic on the Treatment of Jaundice in Full Term Neonates: A Randomized Clinical Trial Shokoufeh Ahmadipour ,1,2 Parastoo Baharvand ,3 Parisa Rahmani ,4 Amin Hasanvand ,5 and Azam Mohsenzadeh 2 1Razi Herbal Medicine Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran 2Department of Pediatrics, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran 3Department of Social Medicine, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran 4Pediatric Gastroenterology and Hepatology Research Center, Tehran University of Medical Sciences, Tehran, Iran 5Department of Pharmacology and Toxicology, Faculty of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran Received: Jun 27, 2018 Revised: Mar 28, 2019 ABSTRACT Accepted: Apr 8, 2019 Purpose: Jaundice accounts for most hospital admissions in the neonatal period. Nowadays, Correspondence to in addition to phototherapy, other auxiliary methods are used to reduce jaundice and the Azam Mohsenzadeh length of hospitalization. This study aimed to investigate the effect of probiotics on the Department of Pediatrics, Faculty of Medicine, Lorestan University of Medical Sciences, treatment of hyper-bilirubinemia in full-term neonates. Anooshirvan Rezaei Square, Khorramabad, Methods: In this randomized clinical trial, 83 full-term neonates, who were admitted to the Lorestan 6813833946, Iran. hospital to receive phototherapy in the first 6 months of 2015, were randomly divided into E-mail: [email protected] two groups: synbiotic (SG, n=40) and control (CG, n=43). Both groups received phototherapy Copyright © 2019 by The Korean Society of but the SG also received 5 drops/day of synbiotics. -
Outbreaks of Nutritional Cardiomyopathy in Pigs in Brazil
Outbreaks of nutritional cardiomyopathy in pigs in Brazil Pesq. Vet. Bras. 38(8):573-579, August 2019 DOI: 10.1590/1678-5150-PVB-6248 Brasil]. [Surtos de cardiomiopatia nutricional em suínos no Original Article Cruz R.A.S., Bassuino D.M., Reis M.O., Laisse C.M.J., Livestock Diseases Pavarini S.P., Sonne L., Kessler A.M. & Driemeier D. 573- ISSN 0100-736X (Print) 579 ISSN 1678-5150 (Online) PVB-6248 LD Outbreaks of nutritional cardiomyopathy in pigs in Brazil1 Raquel A.S. Cruz2 , Daniele M. Bassuino2, Matheus O. Reis2, Cláudio J.M. Laisse2, Saulo P. Pavarin2 , Luciana Sonne2 3 and David Driemeier2* ABSTRACT.- Cruz R.A.S., Bassuino D.M.,, ReisAlexandre M.O., Laisse M. Kessler C.J.M., Pavarini S.P., Sonne L., Kessler A.M. & Driemeier D. 2019. Outbreaks of nutritional cardiomyopathy in pigs in Brazil. Pesquisa Veterinária Brasileira 39(8):573-579. Setor de Patologia Veterinária, Faculdade de Veterinária, Universidade Federal do Rio Grande do Sul, Av. Bento Gonçalves 9090, Porto Alegre, RS 91540-000, Brazil. E-mail: [email protected] Dilated cardiomyopathy (DCM) is a condition that affects the myocardium, seldom reported in pigs. The DCM is characterized by ventricular dilation, which results in systolic and secondary diastolic dysfunction and can lead to arrhythmia and fatal congestive heart studies.failure. This Naturally study describedoccurring thecases clinical, of DCM pathological, in three swine chemical farms and were toxicological investigated findings through of nutritional dilated cardiomyopathy (DCM) in nursery pigs through natural and experimental piglets,necropsy which (fourteen were divided pigs), microscopic, into three groups virological, of three chemical piglets each. -
| Oa Tai Ei Rama Telut Literatur
|OA TAI EI US009750245B2RAMA TELUT LITERATUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,750 ,245 B2 Lemire et al. ( 45 ) Date of Patent : Sep . 5 , 2017 ( 54 ) TOPICAL USE OF AN ANTIMICROBIAL 2003 /0225003 A1 * 12 / 2003 Ninkov . .. .. 514 / 23 FORMULATION 2009 /0258098 A 10 /2009 Rolling et al. 2009 /0269394 Al 10 /2009 Baker, Jr . et al . 2010 / 0034907 A1 * 2 / 2010 Daigle et al. 424 / 736 (71 ) Applicant : Laboratoire M2, Sherbrooke (CA ) 2010 /0137451 A1 * 6 / 2010 DeMarco et al. .. .. .. 514 / 705 2010 /0272818 Al 10 /2010 Franklin et al . (72 ) Inventors : Gaetan Lemire , Sherbrooke (CA ) ; 2011 / 0206790 AL 8 / 2011 Weiss Ulysse Desranleau Dandurand , 2011 /0223114 AL 9 / 2011 Chakrabortty et al . Sherbrooke (CA ) ; Sylvain Quessy , 2013 /0034618 A1 * 2 / 2013 Swenholt . .. .. 424 /665 Ste - Anne -de - Sorel (CA ) ; Ann Letellier , Massueville (CA ) FOREIGN PATENT DOCUMENTS ( 73 ) Assignee : LABORATOIRE M2, Sherbrooke, AU 2009235913 10 /2009 CA 2567333 12 / 2005 Quebec (CA ) EP 1178736 * 2 / 2004 A23K 1 / 16 WO WO0069277 11 /2000 ( * ) Notice : Subject to any disclaimer, the term of this WO WO 2009132343 10 / 2009 patent is extended or adjusted under 35 WO WO 2010010320 1 / 2010 U . S . C . 154 ( b ) by 37 days . (21 ) Appl. No. : 13 /790 ,911 OTHER PUBLICATIONS Definition of “ Subject ,” Oxford Dictionary - American English , (22 ) Filed : Mar. 8 , 2013 Accessed Dec . 6 , 2013 , pp . 1 - 2 . * Inouye et al , “ Combined Effect of Heat , Essential Oils and Salt on (65 ) Prior Publication Data the Fungicidal Activity against Trichophyton mentagrophytes in US 2014 /0256826 A1 Sep . 11, 2014 Foot Bath ,” Jpn . -
Thrombosis, Embolism, Infarction
Thrombosis, Embolism and Infarction THROMBOSIS Thrombus formation (called Virchow's triad): (1) endothelial injury, (2) stasis or turbulent blood flow (3) hypercoagulability of the blood Endothelial Injury Endothelial injury is particularly important for thrombus formation in the heart or the arterial circulation, where the normally high flow rates might otherwise impede clotting by preventing platelet adhesion and washing out activated coagulation factors. Thus, thrombus formation within cardiac chambers (e.g., after endocardial injury due to myocardial infarction), over ulcerated plaques in atherosclerotic arteries, or at sites of traumatic or inflammatory vascular injury (vasculitis) is largely a consequence of endothelial cell injury. Endothelial Injury Physical loss of endothelium can lead to exposure of the subendothelial ECM, adhesion of platelets, release of tissue factor, and local depletion of PGI2 and plasminogen activators. However, it should be emphasized that endothelium need not be denuded or physically disrupted to contribute to the development of thrombosis; any perturbation in the dynamic balance of the prothombotic and antithrombotic activities of endothelium can influence local clotting events. Thus, dysfunctional endothelial cells can produce more procoagulant factors (e.g., platelet adhesion molecules, tissue factor, PAIs) or may synthesize less anticoagulant effectors (e.g., thrombomodulin, PGI2, t-PA). Endothelial dysfunction can be induced by a wide variety of insults, including hypertension, turbulent blood flow, bacterial endotoxins, radiation injury, metabolic abnormalities such as hypercholesterolemia. Alterations in Normal Blood Flow Turbulence contributes to arterial and cardiac thrombosis by causing endothelial injury or dysfunction, as well as by forming countercurrents and local pockets of stasis; stasis is a major contributor in the development of venous thrombi. -
3. Thrombosis. Embolism. DIC. Shock
3. Thrombosis. Embolism. DIC. Shock. PATHOLOGY OF VASCULAR OCCLUSION: thrombosis, embolism, disseminated intravascular coagulation (DIC) Hemostasis (”stopping of hemorrhage”) Physiological process to maintain blood in a fluid, clot-free state in normal vessels, and to stop bleeding from ruptured vessels Main components of hemostasis: endothelium, platelets, and coagulation proteins Endothelial cells have both procoagulant and anticoagulant properties, and according to the needs of the body they may either promote clotting or inhibiting it Procoagulant functions Release of • von Willebrand factor (vWF); mediates the binding of platelets to endothelial surfaces • Tissue factor (TF); promotes the extrinsic pathway of the coagulation cascade • Inhibitors of plasminogen activator Anticoagulant functions • Inhibition of platelet aggregation via prostacyclin secretion • Dilation of blood vessels via nitric oxide secretion • Antithrombin activity, accomplished by thrombomodulin, which captures thrombin • Fibrinolysis, via secreting plasminogen activator, which generates plasmin from plasminogen Platelets Upon contact with TF and/or vWF, platelets become activated and 1) adhere to injured sites 2) release chemical mediators to induce further platelet aggregation, and activation of coagulation proteins 3) aggregate with other platelets and form the hemostatic plug. Both RBCs and leukocytes are also found in hemostatic plugs. Coagulation proteins Group of plasma proteins that are activated by acting upon each other in a sequence known as the extrinsic and intrinsic pathway. These proteins converge, and finally thrombin converts fibrinogen to fibrin within and about the platelet plug. THROMBOSIS • Intravascular clotting in a living person • Clots formed inside the blood vessels or cardiac chambers are called thrombi • Thrombi are always potential sources of further complications Factors promoting thrombus formation (Virchow’s triad) 1.